Key result
BNP and NT-proBNP can diagnose acute heart failure and predict future cardiac events in patients with chronic kidney disease, though a standardized clinical strategy remains lacking.
Why the study?
Does BNP and NT-proBNP testing improve the diagnosis of acute heart failure and prediction of cardiac events in patients with chronic kidney disease?
Does BNP and NT-proBNP testing improve the diagnosis of acute heart failure and prediction of cardiac events in patients with chronic kidney disease?
BNP and NT-proBNP are useful for diagnosing acute heart failure and predicting cardiac events in patients with chronic kidney disease, despite differences in their renal clearance.
May support natriuretic peptide use in CKD with acute HF; leaves open standardized thresholds and prospective validation.
Although there is overwhelming evidence that natriuretic peptides might be helpful in the diagnosis and management of congestive heart failure patients, the relationship among brain natriuretic peptides (BNP), renal function, and the severity of heart failure is less clear. It is obvious that the metabolism and elimination of BNP and N-terminal prohormone brain natriuretic peptide (NT-proBNP) are different with BNP clearance less dependent upon renal function. This paper reviews current data about the diagnostic and predictive role of natriuretic peptides to detect cardiac events in patients with chronic kidney disease. Although BNP and Nt-proBNP can be used to diagnose acute heart failure and may help predict risk and future cardiac events in patients with chronic kidney disease (CKD), a strategy that incorporates their use in daily clinical practice is still lacking.
No takes yet. Share an insight, caveat, or question.
Vanderheyden et al. (2008) conducted a review in Chronic kidney disease and congestive heart failure. Natriuretic peptides (BNP and NT-proBNP) was evaluated on Diagnosis of acute heart failure and prediction of cardiac events. BNP and NT-proBNP can diagnose acute heart failure and predict future cardiac events in patients with chronic kidney disease, though a standardized clinical strategy remains lacking.